Welcome to our dedicated page for Cytek Biosciences SEC filings (Ticker: CTKB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytek Biosciences, Inc. filings document the reporting, governance, and security structure of a Nasdaq-listed cell analysis solutions company. Its registered security is common stock traded under the CTKB symbol on the Nasdaq Global Select Market.
The company’s 8-K filings furnish financial-results releases, preliminary revenue updates, and related exhibit disclosures under Item 2.02. Proxy and annual meeting filings cover director elections, advisory executive compensation votes, auditor ratification, stockholder voting results, board-class matters, and other governance subjects. Together, these filings describe Cytek’s public-company reporting framework alongside its business in FSP instruments, reagents, software, services, and cell analysis technologies.
Cytek Biosciences (CTKB) filed a Form 4 showing a director’s equity activity. On 11/18/2025, the reporting person acquired 2,181 shares of common stock through the vesting and settlement of restricted stock units, reported with transaction code "M." After this transaction, the person directly owned 12,359 shares of common stock.
The filing also shows activity in derivative securities. On the same date, 2,181 restricted stock units were converted into common stock at an exercise price of $0, leaving 13,819 restricted stock units beneficially owned directly. Each restricted stock unit represents a contingent right to receive one share of Cytek Biosciences common stock, subject to a multi-date vesting schedule.
Cytek Biosciences (CTKB) reported an insider equity transaction by a company director on 11/18/2025. The filing shows that 6,107 shares of common stock were acquired through the vesting and settlement of restricted stock units (RSUs), coded as transaction type “M,” which reflects the conversion of a derivative security into common stock.
After this transaction, the director beneficially owns 10,178 shares of Cytek common stock directly and continues to hold 63,111 RSUs. Each RSU represents the right to receive one share of common stock. The RSU award vests over time in tranches on specific dates, including portions vesting on August 18, November 18, March 10, May 18 and August 18 of future years until the award is fully vested.
Cytek Biosciences (CTKB) filed its Q3 2025 10‑Q, reporting total revenue of $52.3 million (product $38.1M; service $14.2M). Gross profit was $27.6 million and loss from operations was $9.2 million, resulting in a net loss of $5.5 million, or $0.04 per share.
Year‑to‑date revenue was $139.4 million with a net loss of $22.5 million. Cash and cash equivalents were $93.3 million, and marketable securities were $168.5 million. Deferred revenue was $28.7 million current and $16.3 million noncurrent, with remaining performance obligations totaling $45.1 million. Operating cash flow for the nine months was $(3.9) million. Shares outstanding were 127,864,830 as of September 30, 2025.
Cytek Biosciences, Inc. furnished a Current Report to announce that it issued a press release with financial results for the quarter ended September 30, 2025.
The press release is included as Exhibit 99.1 and was furnished under Item 2.02. The information furnished under Item 2.02 and the exhibit are not deemed filed under Section 18 of the Exchange Act. Cytek’s common stock trades on the Nasdaq Global Select Market under the symbol CTKB.
Cytek Biosciences director and Chief Technology Officer Yan Ming reported multiple Form 4 transactions on 08/18/2025 related to the vesting of Restricted Stock Units (RSUs). The filings show vesting events that increased Mr. Yan's direct beneficial ownership to 6,058,887 shares of common stock after the reported transactions. Several tranches vested on 08/18/2025 totaling 20,?231 RSUs (1,981 + 7,363 + 5,525 + 6,162) and certain shares were withheld to satisfy tax withholding obligations at a price of $4.06 per share for the withheld amounts. The RSU awards follow multi‑year vesting schedules described in the explanation, with quarterly or annual vesting components.
Insider Form 4 for Cytek Biosciences, Inc. (CTKB) reports that Philippe Busque, SVP, Global Sales and Services and a director, had multiple restricted stock unit (RSU) vesting events on 08/18/2025 that increased his beneficial ownership. A series of RSU awards converted into common shares: 1,536; 2,210; and 3,625 RSUs became vested and reflected as acquired shares. The filing also shows withholding/surrender of shares to satisfy tax obligations related to the vesting, reducing net share additions.
Valerie Barnett, Chief Legal Officer of Cytek Biosciences (CTKB), reported multiple transactions on August 18, 2025 related to restricted stock units (RSUs) that vested. The filing shows vesting and issuance of RSUs in several tranches: 2,016; 3,681; 7,735; and 10,875 units. Shares were withheld to cover tax obligations: 786, 1,434, 3,000 and 3,609 shares respectively. After the reported transactions, Barnett beneficially owned 155,888 shares of common stock.
Insider transactions by Cytek Biosciences (CTKB): The company's President and CEO and a director, Jiang Wenbin, reported multiple transactions on 08/18/2025 relating to Restricted Stock Units (RSUs) that vested. Several RSU awards converted into shares: 6,758; 11,781; 22,100; and 29,002 RSUs were reported as vested and credited as common stock. To satisfy tax withholding on the vesting, the issuer withheld and surrendered shares in amounts of 1,646; 2,869; 5,382; and 7,062 at an indicated price of $4.06 per share. After these transactions, the filing shows beneficial ownership tallies following each line, with reported direct ownership figures such as 5,321,479 shares following the largest aggregation. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
William D. McCombe, Chief Financial Officer and Director of Cytek Biosciences, Inc. (CTKB), reported changes in beneficial ownership related to vesting of restricted stock units on 08/18/2025.
The filing shows two RSU vesting events recorded as acquisitions of 6,320 and 13,051 RSUs (each RSU convertible into one share). To satisfy tax withholding on the vesting, the issuer withheld 2,462 and 5,084 shares at a per-share price of $4.06. Post-transaction ownership figures reported in the form include multiple balances (for common stock and underlying derivative holdings), with derivative share totals of 6,320 and 13,051 underlying shares and aggregate beneficial ownership figures shown in the filing. The RSUs vest over four years on a specified schedule described in the explanations. The form was signed by an attorney-in-fact on 08/20/2025.
Cytek Biosciences director Michael Holder received a grant of 2,181 Restricted Stock Units (RSUs) reported on Form 4 with a transaction date of 08/18/2025. Each RSU converts to one share of common stock upon vesting; the filing shows these RSUs were reported as acquired at a $0 price and increased the reporting person’s beneficial ownership to 10,178 shares following the transaction. The RSU award vests per a schedule described in the filing, with portions vesting on specified dates (including August 18 and November 18 milestones) over multiple years until fully vested.